News Quantified

BTAI – bioxcel therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting [Y

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

-7.7%

BEAT

-21.0%

MISS

-43.8%

MISS

10.7%

MISS

Canaccord Genuity

Form DEFA14A BioXcel Therapeutics,

Form DEF 14A BioXcel Therapeutics, For: Jun 10

Form 8-K BioXcel Therapeutics, For: Apr 22

Form PRE 14A BioXcel Therapeutics, For: Jun 10

Form 8-K BioXcel Therapeutics, For: Apr 10

Top News Gainers

12/31 BioXcel Therapeutics Inc (NASDAQ: BTAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock. 40.3%

2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%

2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%

8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%

1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%

3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%

4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%

4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%

2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%

1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%

Top News Decliners

3/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -26.4%

9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%

3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%

5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%

2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%

3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%

3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%

10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%

5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%

1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day